Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? - Wikidata - wikimedia - TriplyDB

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

http://www.wikidata.org/entity/Q37778944

about

Natalizumab for relapsing remitting multiple sclerosis Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps Progressive multifocal leukoencephalopathy: clinical and molecular aspects Insights into the initiation of JC virus DNA replication derived from the crystal structure of the T-antigen origin binding domain Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.From injection therapies to natalizumab: views on the treatment of multiple sclerosis.Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis The mesenchymal tumor microenvironment: a drug-resistant niche.Cognitive dysfunction with aging and the role of inflammation A review on JC virus infection in kidney transplant recipients.A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis Changes to anti-JCV antibody levels in a Swedish national MS cohort Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.Principles of a new treatment algorithm in multiple sclerosis.Progressive multifocal leukoencephalopathy and natalizumab.What happens when natalizumab therapy is stopped?Treating multiple sclerosis with natalizumab.Integrins as receptor targets for neurological disorders Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.Multiple sclerosis treatment and infectious issues: update 2013.The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.αvβ3- or α5β1-Integrin-Selective Peptidomimetics for Surface Coating.Multiple sclerosis: an example of pathogenic viral interaction?Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.Early magnetic resonance detection of natalizumab-related progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.The cohort of the multiple sclerosis center of Cagliari.

P2860

Q24235861-B8B937C1-6BBA-48E0-9630-06A1BC72EBD0 Q26823444-A092F831-65A5-4E23-B405-421707061453 Q26858968-B9B8D20D-6EEE-49CC-A5BE-73BBF49F9C85 Q27681947-3D2686D4-7187-41C8-951D-755B88CC9458 Q28730755-530BBF83-7988-4841-9B60-4EA3792B35AB Q30408322-80D1A0C2-B4B2-4C79-9861-F0202DD3D900 Q33770508-214D615F-BE6D-4247-92D9-6AD2617AB86A Q34324861-CA0149B9-1177-4271-A93B-A7D186F1BF58 Q34922742-972F809F-2023-43B6-A4F9-A7DB87008A95 Q35212994-22641351-C806-455A-9743-E5BF7B083DCF Q35606563-49757672-6D41-44D7-A06D-3D2549A142D9 Q35825914-E8E2528D-8D01-446F-8DC5-137E0814EA85 Q36145715-C65A6A75-DA1C-40D3-BE9B-8E25B4E29CC9 Q36187755-AD761424-78DA-4E0F-864B-BC1B8C59C1EA Q36443732-AB75F48A-15C3-45AB-B946-97B67297160B Q36602840-DDAD2896-188F-49E1-856A-0E34CBE1D9F8 Q37012710-34DCA4F5-A446-4F47-B586-4F32ECC04D1E Q37267644-75819564-7260-4AE1-8FD7-F7AC106F1AA3 Q37615119-60C810E9-BE73-4B63-835D-AB379B8C0818 Q37849763-C3F5DB5A-E1B5-488C-A60C-B63A25A31210 Q37885823-B2AE16AB-6450-4AC6-98BF-00D11CE8AE97 Q37921761-B4601AF4-0E04-4364-9F8D-51F81F09BEE8 Q37957123-0088983C-528D-4202-879A-2B3872A67814 Q37974737-D6D84C67-7706-4CB7-B3BF-39B822C70DCE Q38029235-07D90D03-AA95-4515-BDA7-ADD92D453A8B Q38068499-265AFA60-0594-430F-9D92-3741020596A3 Q38116451-3231A084-F259-4FB5-9261-F170413C2A82 Q38153471-4EEBC100-5857-4405-825C-17D40092537E Q38186206-FB8D9EE9-86C7-48EE-B645-5D799A6F24EA Q38268951-3FB78C34-E59C-4D70-8994-2B7AB48C09A0 Q38591114-7D8BA993-1647-4059-9EA5-6F02335E1E67 Q38815391-E2B2585C-0DEA-4A82-A3F4-5FF2BC153DB5 Q38852942-2F3FFE09-009A-46DC-964C-6A917A3BAFDC Q39152931-3EBF91AE-8602-49F7-A0BC-C60297A86EFE Q39211049-CFB621E2-8EF0-4C9F-9526-9F32F36C9DCC Q39303279-DB5DD900-E440-4768-9459-B96603872790 Q41102105-FAB55DAF-62FF-4D6F-86C3-FE6D17E906FB Q42181572-902BB6FD-B459-4D71-964E-C3834234FF82 Q42732010-21F8E992-DBDF-4494-A7ED-7B144DAD1255 Q44178125-0859FEAB-9D67-48C0-A1D5-E1BB7A5A289A

P2860

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

http://www.wikidata.org/entity/Q37778944

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Natalizumab and progressive mu ...... factors and can it be avoided?

@en

Natalizumab and progressive mu ...... factors and can it be avoided?

@nl

type

label

Natalizumab and progressive mu ...... factors and can it be avoided?

@en

Natalizumab and progressive mu ...... factors and can it be avoided?

@nl

prefLabel

Natalizumab and progressive mu ...... factors and can it be avoided?

@en

Natalizumab and progressive mu ...... factors and can it be avoided?

@nl

P1433

Q37778944-528DB1CD-EB1F-49DD-9238-AB54A3FDC4CB

P1476

Q37778944-3CCC2DC8-CD67-4FD1-8091-5585F4BA34F4

P2093

Q37778944-0D3C86A8-DEEA-43B6-BFE5-3C2BFC7F4242

Q37778944-15C0CE55-D8DE-4730-94E6-337DD43A467F

Q37778944-1BE20365-FA05-456E-8461-13B8A1A419E7

Q37778944-32DBE043-1667-4FEA-BC0A-523D58E6D223

Q37778944-41724D01-8F83-4DC7-9CBF-1F4342DEDA59

Q37778944-6747103D-9356-467E-A088-DB10A404EF65

Q37778944-AA9639BA-7AED-4675-9326-EBE43A62EE13

Q37778944-BD9D2FEC-C3E7-40C6-83FB-6EBAAF0C1305

Q37778944-CC61B4AF-7AED-4BF0-8DF1-BEE71A727398

Q37778944-F355B433-E73A-419A-BD98-35B946AB5457

P2860

Q37778944-001D1BD9-5E40-4AA9-9657-B9F39B951C9C

Q37778944-0047367F-BE98-424E-8BF1-6DBA941DB595

Q37778944-01AB17A3-FB02-48C9-9313-1F0813B21956

Q37778944-096B79CF-DFB6-4559-AF18-E5E0BAD94FA3

Q37778944-0AB5C2D9-7A7C-42BA-A19F-FBC0038030A0

Q37778944-103ECEAE-0790-49D0-A808-D5991192E039

Q37778944-12187677-B372-45EF-8920-7EE5A713C418

Q37778944-127FCD48-0633-4387-AF70-411924F2A422

Q37778944-14A23FC6-DF4D-4610-BFD2-D1290B88C33C

Q37778944-1F4E9797-7F6F-4AD9-A352-585A099EC763

P304

Q37778944-54DCACFE-EE0E-4359-A3D6-5B3DD00A31DB

P31

Q37778944-C739EF2A-B942-4C26-9F74-57C88A6ED045

P356

Q37778944-C9682D49-E6B4-4863-BFEB-17845F925232

P433

Q37778944-C5A995DF-64D1-40A4-BE0F-20076DA48DE8

P478

Q37778944-AD7E99DE-18F8-4D75-A8FB-657340BC5BA5

P50

Q37778944-00ADBF21-5F57-45CC-BE9F-2D04DD6E0696

Q37778944-348328CE-9CDC-4D52-95A1-473AC049B82C

Q37778944-70E62EBE-8B72-49E6-BD8A-2D740CA26D66

P577

Q37778944-44230DD9-6B05-4E53-BDC6-D97A0C547BFC

P5875

Q37778944-98762CE9-D9C9-40CA-AD76-27B1918E50D2

P698

Q37778944-D9840D69-3125-4F3B-8AD9-7E1F102B6453

P921

Q37778944-19CF6DAC-B8C6-4EAB-B9C3-E5A6BD1C2957

P932

Q37778944-BEE409EC-477A-4D31-B707-20BE88D4922F

P356

ARCHNEUROL.2010.161

P1433

P1476

Natalizumab and progressive mu ...... factors and can it be avoided?

@en

P2093

Benjamin M Greenberg

http://www.w3.org/2001/XMLSchema#string

Bernhard Hemmer

http://www.w3.org/2001/XMLSchema#string

Clemens Warnke

http://www.w3.org/2001/XMLSchema#string

Elliot M Frohman

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Bennett

http://www.w3.org/2001/XMLSchema#string

Michael K Racke

http://www.w3.org/2001/XMLSchema#string

Petra D Cravens

http://www.w3.org/2001/XMLSchema#string

Ralf Gold

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

Til Menge

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Multiple sclerosis

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

The immunopathology of multiple sclerosis: an overview

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Progressive multifocal leukoencephalopathy in transplant recipients.

Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories.

P304

923-930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.2010.161

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Hartung

Bernd C Kieseier

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45583487

http://www.w3.org/2001/XMLSchema#string

P698

20697042

http://www.w3.org/2001/XMLSchema#string

P921

progressive multifocal leukoencephalopathy

P932

4157908

http://www.w3.org/2001/XMLSchema#string